| pubmed-article:8445422 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8445422 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:8445422 | lifeskim:mentions | umls-concept:C0001554 | lld:lifeskim |
| pubmed-article:8445422 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:8445422 | lifeskim:mentions | umls-concept:C0278488 | lld:lifeskim |
| pubmed-article:8445422 | lifeskim:mentions | umls-concept:C0332174 | lld:lifeskim |
| pubmed-article:8445422 | lifeskim:mentions | umls-concept:C0010583 | lld:lifeskim |
| pubmed-article:8445422 | lifeskim:mentions | umls-concept:C0014582 | lld:lifeskim |
| pubmed-article:8445422 | lifeskim:mentions | umls-concept:C0016360 | lld:lifeskim |
| pubmed-article:8445422 | lifeskim:mentions | umls-concept:C0600688 | lld:lifeskim |
| pubmed-article:8445422 | lifeskim:mentions | umls-concept:C0040808 | lld:lifeskim |
| pubmed-article:8445422 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:8445422 | pubmed:dateCreated | 1993-4-6 | lld:pubmed |
| pubmed-article:8445422 | pubmed:abstractText | To compare the effect on toxicity and efficacy of the fluorouracil 500 mg/m2, epirubicin 60 mg/m2, and cyclophosphamide 500 mg/m2 (FEC) regimen divided into 4 weekly doses with conventional every-4-week administration in metastatic breast cancer. | lld:pubmed |
| pubmed-article:8445422 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8445422 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8445422 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8445422 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8445422 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8445422 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8445422 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8445422 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:8445422 | pubmed:issn | 0732-183X | lld:pubmed |
| pubmed-article:8445422 | pubmed:author | pubmed-author:NevasaariKK | lld:pubmed |
| pubmed-article:8445422 | pubmed:author | pubmed-author:BlomqvistCC | lld:pubmed |
| pubmed-article:8445422 | pubmed:author | pubmed-author:ElomaaII | lld:pubmed |
| pubmed-article:8445422 | pubmed:author | pubmed-author:RissanenPP | lld:pubmed |
| pubmed-article:8445422 | pubmed:author | pubmed-author:HelleLL | lld:pubmed |
| pubmed-article:8445422 | pubmed:author | pubmed-author:HietanenPP | lld:pubmed |
| pubmed-article:8445422 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8445422 | pubmed:volume | 11 | lld:pubmed |
| pubmed-article:8445422 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8445422 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8445422 | pubmed:pagination | 467-73 | lld:pubmed |
| pubmed-article:8445422 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:8445422 | pubmed:meshHeading | pubmed-meshheading:8445422-... | lld:pubmed |
| pubmed-article:8445422 | pubmed:meshHeading | pubmed-meshheading:8445422-... | lld:pubmed |
| pubmed-article:8445422 | pubmed:meshHeading | pubmed-meshheading:8445422-... | lld:pubmed |
| pubmed-article:8445422 | pubmed:meshHeading | pubmed-meshheading:8445422-... | lld:pubmed |
| pubmed-article:8445422 | pubmed:meshHeading | pubmed-meshheading:8445422-... | lld:pubmed |
| pubmed-article:8445422 | pubmed:meshHeading | pubmed-meshheading:8445422-... | lld:pubmed |
| pubmed-article:8445422 | pubmed:meshHeading | pubmed-meshheading:8445422-... | lld:pubmed |
| pubmed-article:8445422 | pubmed:meshHeading | pubmed-meshheading:8445422-... | lld:pubmed |
| pubmed-article:8445422 | pubmed:meshHeading | pubmed-meshheading:8445422-... | lld:pubmed |
| pubmed-article:8445422 | pubmed:meshHeading | pubmed-meshheading:8445422-... | lld:pubmed |
| pubmed-article:8445422 | pubmed:meshHeading | pubmed-meshheading:8445422-... | lld:pubmed |
| pubmed-article:8445422 | pubmed:meshHeading | pubmed-meshheading:8445422-... | lld:pubmed |
| pubmed-article:8445422 | pubmed:meshHeading | pubmed-meshheading:8445422-... | lld:pubmed |
| pubmed-article:8445422 | pubmed:meshHeading | pubmed-meshheading:8445422-... | lld:pubmed |
| pubmed-article:8445422 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8445422 | pubmed:articleTitle | Influence of treatment schedule on toxicity and efficacy of cyclophosphamide, epirubicin, and fluorouracil in metastatic breast cancer: a randomized trial comparing weekly and every-4-week administration. | lld:pubmed |
| pubmed-article:8445422 | pubmed:affiliation | Department of Radiotherapy, University of Helsinki, Finland. | lld:pubmed |
| pubmed-article:8445422 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8445422 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8445422 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:8445422 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:8445422 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8445422 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8445422 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8445422 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8445422 | lld:pubmed |
